Pharmaceuticals News and Research

RSS

SAMHSA: Drug-related intentional poisonings result in 14,720 ED visits during 2009

Intentional poisoning refers to attempts to physically harm someone or render that person defenseless against crimes by deliberately getting them to ingest, inhale or in some other way take in a potentially harmful substance without their knowledge.

11 Nov 2011

Ampion safe and effective for patients with nasal inflammation

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced that an IRB approved, randomized, vehicle-controlled, double-blinded study conducted at Centers for Allergy and Asthma in Denver, Colorado indicates that Ampion provides safe and effective anti-inflammatory relief when administered intranasally to patients with nasal inflammation.

11 Nov 2011

NCCN ORP to evaluate clinical effectiveness of Boehringer Ingelheim's Afatinib in solid tumors

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of Afatinib (BIBW 2992) in solid tumors, including breast, head and neck, and non-small cell lung (NSCL) cancers.

11 Nov 2011

Provectus announces data from Phase 2 PV-10 metastatic melanoma study

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting.

11 Nov 2011

Watson receives FDA approval for generic Kadian ANDA

Watson Pharmaceuticals, Inc. today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for morphine sulfate extended-release capsules USP, the generic equivalent of Actavis' Kadian.

11 Nov 2011

Novartis files suit against Watson over generic Exelon

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rivastigmine transdermal system patches, 4.6 mg/24 hr and 9.5 mg/24 hr.

11 Nov 2011

FarmaSyn implements Cegedim Relationship Management's Mobile Intelligence for iPad solution

Cegedim Relationship Management today announced that FarmaSyn SA has fully deployed Cegedim Relationship Management's award winning Mobile Intelligence for iPad™ solution. Farmasyn SA is a leading Greek pharmaceutical wholesaler and marketing/sales agent of products.

10 Nov 2011

FDA claims withdrawal process for animal antibiotics as too hard

On Monday, in a disappointing move, the U.S. Food and Drug Administration (FDA) denied two citizen petitions that asked the Agency to ban certain uses of antibiotics in food animals.

10 Nov 2011

IRCM peptide chemist listed as inventor on two U.S. patents

In 2010, after more than 10 years of basic research, Dr. Peter W. Schiller, a world-renowned peptide chemist and Director of the Chemical Biology and Peptide research unit at the Institut de recherches cliniques de Montr-al (IRCM), and his international collaborators were the listed inventors on two U.S. patents awarded to the institute and covering different uses of a unique class of peptide compounds initially synthesized in Dr. Schiller's laboratory at the IRCM.

10 Nov 2011

Mylan acquires rights to Pfizer's inhalation technology platform

Mylan Inc. today announced that it has entered into an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize Pfizer's generic equivalent to GlaxoSmithKline's Advair Diskus and Seretide Diskus incorporating Pfizer's proprietary dry powder inhaler delivery platform.

10 Nov 2011

Clinilabs to utilize NewCardio's QTinno in Phase I trial of new CNS drug

NewCardio, Inc., a cardiovascular diagnostic solutions developer, announced today that its strategic partner, Clinilabs, will utilize QTinno, NewCardio's automated cardiac safety solution, to conduct a Phase I trial of an investigational new drug under development for a central nervous system (CNS) indication.

10 Nov 2011

DATATRAK third quarter revenue increases 13% to $2.1 million

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its operating results for the third quarter of 2011.

10 Nov 2011

PDI third quarter revenues increase 4% to $37.2 million

PDI, Inc., today reported financial and operational results for the third quarter ended September 30, 2011.

10 Nov 2011

Transgenomic third quarter total revenue increases 87% to $8.3 million

Transgenomic, Inc. today reported financial results for the three and nine months ended September 30, 2011 and provided a business update.

10 Nov 2011

BioSante third quarter net loss increases to $12.7 million

BioSante Pharmaceuticals, Inc. today announced financial results for the third quarter ended September 30, 2011 and provided an update on the Company's pipeline.

9 Nov 2011

Enrollment complete in Anacor's first of two tavaborole Phase 3 trials for onychomycosis

Anacor Pharmaceuticals announced today that it has completed enrollment in the first of two Phase 3 trials of tavaborole (formerly known as AN2690), a topical anti-fungal product candidate for the treatment of onychomycosis.

9 Nov 2011

ACADIA third quarter revenues decrease to $584,000

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the third quarter ended September 30, 2011.

9 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

BioClinica third quarter service revenues increase 4.1% to $16.6 million

BioClinica, Inc., a global provider of clinical trial management and technology solutions, today announced its financial results for the third quarter and nine months ended September 30, 2011.

From Clario 9 Nov 2011

Salix to acquire Oceana Therapeutics

Oceana Therapeutics LLC, a privately owned global company focused on commercializing best-in-class specialty therapeutics, today announced it has entered into a definitive agreement for the sale of its operating subsidiary, Oceana Therapeutics, Inc. to Salix Pharmaceuticals, Ltd. of Raleigh, NC.

9 Nov 2011